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1. Introduction 
Following an examination of the available information on 5-(2-aminopropyl)indole (5-IT) 
(1), on 3 October 2012 the EMCDDA and Europol launched a Joint Report on the 
substance. It was presented to the Council of the European Union, the European 
Commission and the European Medicines Agency on 12 December 2012 (2,3).  
 
Consequently, a Technical report will be prepared as a matter of priority within a tight 
deadline in order to be available for the risk assessment as requested by the Council of 
the European Union. As identified in the Joint report, there is a lack of information on 
the pharmacology and toxicology of 5-(2-aminopropyl)indole. However, a single study 
published in the 1960s indicated that the substance may act as an inhibitor of 
monoamine oxidase (Cerletti et al., 1968). In some of the non-fatal intoxications and 
deaths associated with 5-(2-aminopropyl)indole that have been reported, symptoms 
typical of monoaminergic toxicity have been noted. These include hyperthermia along 
with dilated pupils, sweating, increased heart rate, high blood pressure, agitation, 
restlessness, disorientation and anxiety. The purpose of the contract therefore is to 
conduct in vitro studies on 5-(2-aminopropyl)indole to investigate its effects on 
monoamine oxidase in order to inform the risk assessment. 
2. Objectives of the study 
Experimental work was conducted to determine and evaluate the effect of 5-(2-
aminopropyl)indole (5-IT) on the human monoamine oxidase (MAO) enzyme. In vitro 
assays included the use of recombinant MAO enzymes and kynuramine as substrate. 
Following incubation, the assays were analysed using previously validated methods 
based on the analysis of the reaction products by HPLC coupled to Diode Array 
Detector (DAD) and fluorescence detection. The two isoenzymes MAO-A and -B were 
considered. The inhibition parameters, IC50 (concentration of inhibitor that produce 50 
% inhibition) and Ki (dissociation constant of enzyme and inhibitor), were determined 
using different concentrations of substrate and inhibitor and appropriate equations. 
Inhibition of MAO-A by known inhibitors was also evaluated and the inhibition 
                                                          
(1) For the purpose of this report the abbreviation ‘5-IT’ is used interchangeably with ‘5-(2-
 aminopropyl)indole’. 
(2)  OJ L 127, 20.5.2005, p. 32. 
(3)  EMCDDA and Europol. (2012), EMCDDA–Europol Joint Report on a new psychoactive substance: 5-(2-
aminopropyl)indole, EMCDDA, Lisbon. 
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parameters (IC50) determined. In addition, experimental work was undertaken on the 
mode of binding of 5-IT, its mechanism of inhibition and selectivity.  
3. Experimental  
Recombinant human monoamine oxidase-A and B were obtained from Gentest BD 
biosciences (Woburn, MA, USA). Kynuramine dihydrobromide, 4-hydroxyquinoline, 
harmaline, clorgyline, R-deprenyl, toloxatone (5-(hydroxymethyl)-3-(3-methylphenyl)-2-
oxazolidinone), and moclobemide (4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide) were 
purchased from Sigma-Aldrich. 5-IT hemisuccinate (5-API hemisuccinate; 5-(2-
aminopropyl)indole hemisuccinate) was purchased from LGC standards. All test 
compounds were dissolved in milli-q ultrapure water and diluted appropriately in 100 
mM phosphate buffer pH 7.4. 
3.1. Monoamine oxidase assays (MAO-A and B) 
The enzymatic activity of human MAO isozymes was studied using protein fractions 
containing this enzyme by using kynuramine as a non-selective substrate (Herraiz and 
Chaparro, 2006). The reaction velocity v (µM/min) was obtained from oxidative 
deamination of kynuramine to form under the conditions of the assay 4-
hydroxyquinoline that was analysed by HPLC-DAD and its concentration calculated 
from a calibration curve of peak area (λ at 320 nm) against concentration (Herraiz and 
Caparro, 2006). To carry out the assay, protein fractions containing MAO-A or B were 
diluted to the desired concentrations in 100 mM potassium phosphate buffer (pH 7.4). 
A 0.2 ml reaction mixture containing 0.01–0.02 mg/ml protein and 0.25 mM kynuramine 
in 75 mM potassium phosphate (pH 7.4) was incubated at 37 ºC for 40 min. After 
incubation the reaction was stopped by the addition of 2N NaOH (75 µl), followed by 
the addition of 70 % perchloric acid (25 µl), and the sample centrifuged (10000 x g) for 
6 min. An aliquot of the supernatant (20 µl) was injected into the HPLC and the 
deamination products of kynuramine formed during the enzymatic reaction determined 
by RP-HPLC-DAD and fluorescence detection.  
3.2. MAO-A and -B inhibition studies with 5-IT and other inhibitors 
MAO-A or -B enzymes were incubated as above with kynuramine as a substrate and 
added with increasing concentrations of 5-IT or other inhibitors of MAO-A and B at the 
desired concentration in phosphate buffer (pH 7.4), and incubated at 37 ºC for 40 min, 
as above. IC50 values (concentration of inhibitor producing 50 per cent inhibition of 
enzymatic activity) were calculated by fitting (% inhibition vs. concentration of inhibitor) 
to non-linear regression curves or by linear regression of inhibition (%) against the log 
of substrate concentration. Assays were carried out at least in duplicate. 
  
Kinetic constant of Michaelis-Menten (Km) and the maximum velocity (Vmax) were 
obtained from nonlinear regression analysis (velocity vs. concentration) using different 
concentrations of substrate. The mechanism of MAO inhibition by 5-IT was assessed 
experimentally by obtaining the corresponding double reciprocal Lineweaver-Burk plots 
of the enzyme activity at different concentrations of substrate and inhibitor. The 
secondary plot of the slope from the double reciprocal curves versus the concentration 
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of inhibitor was used to calculate Ki (inhibition constant) values. Kinetic assays were 
carried out at least in duplicate. 
 
To determine the type of binding of 5-IT to MAO-A (i.e. reversible or irreversible 
inhibition), MAO-A (0.025 mg/ml protein) in 100 mM phosphate buffer (pH 7.4) was 
incubated at 37 ºC for 30 min with or without (control) 5-IT (100 µM), and then 
centrifuged (15000 x g, 15 min) to pellet the protein, that was washed with 100 mM 
phosphate buffer and the procedure repeated three times. Finally, the enzyme was 
resuspended in phosphate buffer and used to measure MAO activity, as above. Assays 
were carried out at least in duplicate. 
3.3. Chromatographic analysis by RP-HPLC  
The analysis of the kynuramine deamination product 4-hydroxyquinoline was 
accomplished by RP-HPLC-DAD and fluorescence detection using an HPLC 1050 
(Hewlett Packard) provided with a 1100 DAD (Agilent) and a 1046A-fluorescence 
detector (Hewlett Packard). A 150 mm x 3.9 mm, 4 µm, Nova-pak C18 column 
(Waters, Milford, MA, USA) was used for separation. Chromatographic conditions 
were: 50 mM ammonium phosphate buffer (pH 3) (buffer A) and 20% of A in 
acetonitrile (buffer B). Gradient programmed from 0 % (100 % A) to 32 % B in 8 min 
and then 90 % B at 10 min. The flow rate was 1 ml/min, the column temperature was 
40 ºC and the injection volume was 20 µl.  
4. Results  
A) In vitro inhibition of human MAO-A by 5-IT 
Enzymatic reactions were carried out at different concentrations of substrate and the 
results of the enzyme activity against the concentration of substrate fitted to nonlinear 
regression analysis to plot Michaelis-Menten curves (Figure 1). The reaction velocity v 
(µM/min) was obtained from the deamination of kynuramine by MAO-A to form 4-
hydroxyquinoline. In that way, calculated values of Vmax of 0.8 ± 0.02 µM/min and Km of 
61.88 ± 4.6 µM were obtained for MAO-A and kynuramine. Subsequently, inhibition of 
human MAO-A by the substance 5-(2-aminopropyl)indole (5-IT) was studied in 
presence of kynuramine as the substrate (250 µM). The profile is shown in Figure 2, 
and it clearly suggests that 5-IT is an in vitro inhibitor of the human MAO-A with an IC50 




Figure 1. Michaelis-Menten curve of kynuramine deamination to form 4-hydroxyquinole by MAO-A (0.01 mg/ml MAO-A 
protein and kynuramine in 0.2 ml phosphate buffer. 37 ºC, 40 min). 
 
 
Figure 2. Inhibition of human MAO-A in presence of 5-IT 
 B) In vitro inhibition of human MAO-B by 5-IT 
Inhibition of human MAO-B by the substance 5-IT was studied in the presence of 
kynuramine as substrate (250 µM). The profile obtained is shown in Figure 3 and 
clearly shows that 5-IT was devoid of activity as an inhibitor of recombinant human 
MAO-B. Indeed, in the range used (0–500 µM, 5-IT) no inhibition of MAO-B was 
detected. Instead, under the same conditions, R-deprenyl, a selective inhibitor of MAO-
B, highly inhibited this enzyme at sub-micromolar concentrations (Figure 4). As a result 
of these data, no further studies were carried out with MAO-B isoenzyme and 5-IT. 
 
Figure 3. Activity of human MAO-B in presence of 5-IT. 
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Figure 4. Inhibition of human MAO-B by (R)-deprenyl. 
C) Kinetic study of human MAO-A inhibition and determination of Ki (inhibition 
constant) values 
As 5-IT was an inhibitor of human MAO-A, kinetic assays corresponding to the activity 
of this enzyme in the presence of increasing concentrations of 5-IT (0–2 µM) were 
accomplished by using various concentration of substrate. The corresponding double 
reciprocal curves (i.e. Lineweaver-Burk plots) were obtained experimentally and are 
given in Figure 5, showing that 5-IT is a competitive inhibitor of MAO-A. Thus, in the 
presence of increasing concentrations of 5-IT, the enzyme had similar Vmax (velocity in 
high concentrations of substrate) whereas Km increased with the concentration of 
inhibitor. The inhibition constant Ki (dissociation constant of the enzyme-inhibitor 
complex) was calculated from a secondary plot of the slopes of curves in Figure 5 
against the concentration of inhibitor giving a value of Ki of 0.25 µM (Figure 6) 
(intercept on the x-axis).  
 
On the other hand, as the inhibition of 5-IT over MAO-A is competitive and the inhibitor 
is reversible (see below), the equation of Cheng-Prusoff (i.e. IC50 = Ki (1 + S/Km) could 
be used to determine Ki from the IC50 and Km values (Cheng and Prusoff, 1973). The Ki 
obtained was 0.32 µM which is in good agreement with the one calculated 







Figure 5. Lineweaver-Burk plot of the MAO-A enzymatic reaction in presence of increased concentrations of 5-IT and 
kynuramine used as substrate. Control without 5-IT (■); 0.5 µM 5-IT (▲); 1 µM 5-IT (▼); 2 µM 5-IT (♦).  
 
Figure 6. Secondary plot of slope of the curves of Lineweaver-Burk plot against the concentration of 5-IT as an inhibitor 
that was used to calculate Ki.  
D) Type of binding (reversibility) of 5-IT with MAO-A  
Following incubation of the enzyme MAO-A with 5-IT, and after washing to completely 
remove the 5-IT, the activity of the enzyme was fully recovered when compared with a 
control incubated in absence of 5-IT. Therefore, 5-IT binds to MAO-A under a 
reversible type of binding (Figure 7). 
 
 
Figure 7. Human MAO-A (0.025 mg/ml, protein conc.) was incubated in duplicate with 0 or 100 µM 5-IT at 37 ºC, 30 
min. The 5-IT removed through successive washing and centrifugation and then enzymatic assay was conducted. 
E) Inhibition of MAO-A by substances used as reference and established inhibitors 
Experimental data of the substance 5-IT as an inhibitor of MAO-A were compared with 
data obtained from other known inhibitors. For that, several substances including 
established inhibitors of MAO-A were studied under the experimental conditions used 
here. Clorgyline, a well-known irreversible inhibitor of MAO-A, demonstrated strong 
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inhibition of human MAO-A with an IC50 under the experimental conditions used of 16 ± 
2.6 nM (Figure 8). Similarly, the β-carboline harmaline, that is a reversible and potent 
inhibitor of MAO-A provided an IC50 of 20 nM (Figure 9).  
 
Figure 8. Inhibition of MAO-A by clorgyline.  
 
 
Figure 9. Inhibition of MAO-A by harmaline. 
 
Toloxatone (Humoryl), an antidepressant launched in 1984 for the treatment 
of depression and which acts as a selective reversible inhibitor of MAO-A (Berlin et 
al.,1990) gave an IC50 of 6.71 ± 0.42 µM (Figure 10). Finally, moclobemide, another 
antidepressant that is authorised as a medicinal product in some countries and also a 
selective reversible MAO-A inhibitor, gave a poor inhibition of MAO-A in vitro with a 
IC50 value higher than 500 µM in our assay system (Figure 11). Results obtained with 
moclobemide suggest that it may be a poor inhibitor of MAO-A in vitro although a good 
inhibitor of MAO-A in vivo, probably resulting from a metabolite of the substance 




Figure 10. Inhibition of MAO-A by toloxatone. 
 
 
Figure 11. Inhibition of MAO-A by moclobemide.  
 
According to the Cheng-Prusoff equation, the Ki obtained for the mentioned 
compounds were 0.016 µM (clorgyline), 0.004 µM (harmaline), and 1.34 µM 
(toloxatone), respectively. Results obtained for harmaline and toloxatone were in good 
agreement with previous reports (Herraiz et al., 2010; Strolin-Benedetti et al., 1983). 
 
Table 1. MAO-A inhibition values of compounds. 
Compound IC50 (µM) Ki (µM) Ki (µM) from IC50 
5-(2-Aminopropyl)indole (5-IT) 1.6 0.25 0.32 
Clorgyline 0.016 - 0.016 
Harmaline 0.020 - 0.004 
Toloxatone 6.7 - 1.3 
Moclobemide >500 - - 
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5. Discussion 
The results indicate that 5-IT is an inhibitor of human MAO-A (Ki of 0.25 µM) (Table 1). 
Nevertheless, this value suggests that its potency as a MAO-A inhibitor is at least ten 
times lower than that of clorgyline (i.e. Ki 0.016 µM) that is an irreversible inhibitor of 
this enzyme. It is also lower than that of the β-carboline harmaline that is also a potent 
reversible inhibitor of MAO-A (IC50 of 1.6 µM for 5-IT vs. 0.020 µM for harmaline). 
However, 5-IT was apparently a more potent inhibitor in vitro than toloxatone and 
moclobemide. It is known that MAO-A inhibitors and antidepressants working as MAO 
inhibitors result in an increase of serotonin levels in vivo. It cannot be ruled out that 
recreational use of 5-IT could elevate serotonin levels by itself or in combination with 
other substances.  
 
These results indicate that 5-IT is a highly selective inhibitor of MAO-A, which is a 
property also shared by α-methyltryptamine (Tipton et al., 1982). Although the 5-IT 
structure contains a phenethylamine moiety it did not inhibit MAO-B. The ability of 5-IT 
to potentiate the hypertensive effects (‘cheese effect’) related to consumption of 
tyramine containing-foods cannot be fully excluded (Finberg and Gillman, 2011). 
  
In a previous report, Cerletti et al., (1968) studied the inhibition of MAO by 5-IT and its 
positional isomers. These authors reported a value of IC50 of 22 µM for 5-IT which was 
higher (i.e. less potent as an inhibitor) than the value reported here. Those differences 
might be attributed to the different assays as well as enzyme sources and fractions 
used. The assay of Cerletti et al., was based on the ability of guinea pig liver 
homogenate to uptake oxygen in an assay that used serotonin as the substrate of 
MAO, whereas recombinant human MAO enzymes and kynuramine deamination were 
used in the current study. In the same study, Cerletti et al., (1968) reported an 
antagonist effect of pentylenetetrazole/reserpine (an antihypertensive drug) that might 
also be related to MAO inhibition. Previous results of Cerletti et al., (1968) and those 
reported here point to 5-IT as a selective inhibitor of MAO-A in the low micromolar 
range. Those results suggest that 5-IT by itself or in combination with other substances 
could potentiate serotonergic effects. However, further pharmacological and in vivo 
studies are needed to clarify this action and its relevance to the toxicological effects of 
5-IT 
6. Conclusions 
The results from this study lead to the following conclusions concerning 5-(2-
aminopropyl)indole (5-IT): 
 
1) 5-IT is an inhibitor of MAO-A with an IC50 of 1.6 µM and Ki of 0.25 µM.  
2) 5-IT is a reversible inhibitor of MAO-A.  
3) 5-IT is a competitive inhibitor of MAO-A.  
4) 5-IT is a highly selective inhibitor of MAO-A, and does not inhibit MAO-B.  
5) Under the experimental conditions used here, other established inhibitors of MAO-A 
and antidepressants provided the following IC50 values: clorgyline 0.016 µM, 
harmaline 0.020 µM, toloxatone 6.7 µM and moclobemide > 500 µM. In other words, 
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5-IT was less potent than clorgyline and harmaline and more potent than toloxatone 
and moclobemide.  
 
In summary, 5-IT is a relatively potent, reversible and selective inhibitor of MAO-A in 
vitro. In this regard it might increase monoamine levels, particularly serotonin. 
However, in order to clarify the significance of these results, further pharmacological 
and in vivo studies are needed to demonstrate MAO-A inhibition in vivo as well as an 
increase of serotonin and potential monoaminergic toxicity due to the use of 5-IT–
containing drugs.  
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